On March 2, 2017 Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in Washington, D.C. from April 1-5, 2017. These abstracts include a clinical data presentation from the dose-escalation phase of the Company’s ongoing trial of its selective FGFR 1/2/3 inhibitor (INCB54828), and well as preclinical data from its small molecule inhibitor programs targeting PI3Kδ (INCB50465), LSD1 (INCB59872), JAK1 (INCB52793), BRD/BET (INCB54329 and INCB57643) and FGFR4 (INCB62079) and from its epacadostat, OX40 (INCAGN1949) and GITR (INCAGN1876) immuno-oncology programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The 20 abstracts to be presented at the upcoming AACR (Free AACR Whitepaper) annual meeting underscore the breadth and potential of our innovative pipeline of oncology product candidates," stated Reid Huber, Ph.D., Chief Scientific Officer, Incyte. "We are pleased to share these new data with the scientific community, and look forward to progressing these and the other clinical programs in our growing portfolio."

Key abstracts, including Incyte-sponsored and independent investigator-sponsored studies, include:
Targeted therapies abstracts
Activity of the Selective FGFR 1, 2 and 3 Inhibitor INCB54828 in Genetically-Defined Models of Triple-Negative Breast Cancer (Abstract #531)
Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 22
Preclinical Studies on Potential Therapeutic Combination Partners for the Potent and Selective PI3K Inhibitor INCB50465 in DLBCL (Abstract #143)
Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 6
The Evaluation of INCB59872, an FAD-Directed Covalent Inhibitor of LSD1, in Preclinical Models of Ewing Sarcoma (Abstract #1162)
Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 5
The Novel FGFR4-selective Inhibitor INCB62079 is Efficacious in Models of Hepatocellular Carcinoma Harboring FGF19 Amplification (Abstract #1234)
Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 7
Mechanisms of Bromodomain and Extra-Terminal Motif Inhibitor (BETi) Sensitivity in Triple-Negative Breast Cancer (TNBC) (Abstract #1518)
Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 20
Selective Inhibition of FGFR4 by INCB62079 is Efficacious in Models of FGF19- and FGFR4-Dependent Cancers (Abstract #2100)
Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33
Combination of Epigenetic Regulation with Targeted Therapies Significantly Enhances Anti-Tumor Effects in Hematologic Malignancy Models (Abstract #2032)
Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 4
Preliminary Results from a Phase 1/2 Study of INCB54828, a Highly Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients (pts) with Advanced Malignancies (Abstract #CT111)
Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 33
INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit expansion of AML (Abstract #3726)
Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 29
The LSD1 Specific Inhibitor INCB59872 Enhances the Activity of Immune Checkpoint Blockade by Reshaping the Myeloid Compartment in the Syngeneic 4T1 Mouse Mammary Tumor Model (Abstract #4635)
Tuesday, April 4, 2017, 1:00-5:00 p.m. EDT, Poster Section 27
The Selective Bromodomain Inhibitor, INCB54329 Targets both Cancer Cells and the Tumor Microenvironment in the KC Inflammatory Preclinical Model of Ductal Pancreatic Cancer (Abstract #5082)
Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2
BET Inhibitors INCB54329 and INCB57643 Display Significant Activity in Androgen-Independent Prostate Cancer Models (Abstract #5080)
Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2
Preclinical Characterization of the Potent and Selective BET Inhibitor INCB57643 in Models of Hematologic Malignancies (Abstract #5071)
Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2
Immuno-oncology abstracts
Inhibition of IDO1 with Epacadostat Enhances Anti-Tumor Efficacy of PD-1 Blockade in a Syngeneic Glioblastoma (GBM) Model (Abstract #572)
• Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 25
Agonist Antibodies Targeting OX40 and GITR Enhance the Activity of the IDO1-Selective Inhibitor Epacadostat in Preclinical Models (Abstract #2618)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 25
INCAGN1876, a Unique GITR Agonist Antibody that Facilitates GITR Oligomerization (Abstract #3643)
• Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 26
INCAGN1949, an Anti-OX40 Antibody with an Optimal Agonistic Profile, with the Ability to Selectively Deplete Intratumoral Regulatory T Cells in a Range of Tumor Indications (Abstract #4703)
• Tuesday, April 4, 2017, 1:00-5:00 p.m. EDT, Poster Section 30
Trials-in-progress abstracts
Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB54828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement (Abstract #CT057)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33
Phase 2, Open-label, Multicenter Study of the Efficacy and Safety of INCB54828 for Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Alterations (Abstract #CT059)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33
Phase 2, Open-label, Multicenter Study of the Efficacy and Safety of INCB54828 in Patients with Advanced, Metastatic, or Surgically Unresectable Cholangiocarcinoma (CCA) With Inadequate Response to Prior Therapy (Abstract #CT063)
• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33
Full session details and data presentations at the AACR (Free AACR Whitepaper) 2017 can be found here.